|
| 37433376 | Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial. | Int J Radiat Oncol Biol Phys | 2024 |
| 36892847 | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37588161 | Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment. | Digit Health | 2023 |
| 37450351 | Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. | Cancer Res | 2023 |
| 37410096 | Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 36401732 | The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HRâ¿¿+â¿¿/HER2â¿¿-) advanced/metastatic breast cancer. | Breast Cancer Res Treat | 2023 |
| 33973154 | Subjective cognition and mood in persistent chemotherapy-related cognitive impairment. | J Cancer Surviv | 2022 |
| 35545724 | Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. | Breast Cancer Res Treat | 2022 |
| 35608580 | Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. | JAMA | 2022 |
| 36304942 | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. | Cancer Res Commun | 2022 |
| 36083147 | FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. | Appl Immunohistochem Mol Morphol | 2022 |
| 34874182 | Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). | J Clin Oncol | 2022 |
| 34995105 | Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). | J Clin Oncol | 2022 |
| 34903452 | A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). | Clin Breast Cancer | 2022 |
| 32986828 | Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. | J Natl Cancer Inst | 2021 |
| 33602685 | Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. | Clin Cancer Res | 2021 |
| 33780274 | Patient-Reported Outcomes in Patients With <i>PIK3CA</i>-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. | J Clin Oncol | 2021 |
| 33527137 | The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. | J Natl Cancer Inst | 2021 |
| 34794122 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. | J Natl Compr Canc Netw | 2021 |
| 34411071 | New targets in endocrine-resistant hormone receptor-positive breast cancer. | Clin Adv Hematol Oncol | 2021 |
| 34554848 | Reply to T. Shimoi et al and Y. Shimanuki et al. | J Clin Oncol | 2021 |
| 34485814 | Cancer Antigen 15-3/Mucin 1â¿¿Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. | JNCI Cancer Spectr | 2021 |
| 34394194 | Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases. | Front Genet | 2021 |
| 34103538 | Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. | NPJ Breast Cancer | 2021 |
| 33941592 | Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. | Cancer Discov | 2021 |
| 34069042 | Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. | Int J Mol Sci | 2021 |
| 34092112 | Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. | J Clin Oncol | 2021 |
| 34331630 | Impact of molecular subtype and race on HR+, HER2- breast cancer survival. | Breast Cancer Res Treat | 2021 |
| 33089889 | At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. | J Leukoc Biol | 2021 |
| 33246021 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. | Ann Oncol | 2021 |
| 33272926 | Racial/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer. | Cancer Res | 2021 |
| 33475287 | Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis. | Cancer J | 2021 |
| 33183970 | Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. | Clin Breast Cancer | 2021 |
| 32838477 | Radiotherapy after breast-conserving surgery for elderly patients with early-stage breast cancer: A national registry-based study. | Int J Cancer | 2021 |
| 31566680 | Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 31809877 | Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer. | Int J Radiat Oncol Biol Phys | 2020 |
| 31806627 | Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer. | Cancer Discov | 2020 |
| 31748278 | Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 32066870 | Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. | Genet Med | 2020 |
| 32946924 | Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. | Ann Oncol | 2020 |
| 32826327 | Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. | Clin Cancer Res | 2020 |
| 32995820 | Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. | medRxiv | 2020 |
| 32767201 | Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. | Breast Cancer Res Treat | 2020 |
| 32894420 | Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. | Drugs | 2020 |
| 32312891 | Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer. | Clin Cancer Res | 2020 |
| 32416251 | Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. | Ann Oncol | 2020 |
| 32298357 | Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. | PLoS One | 2020 |
| 32234364 | Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity. | Clin Breast Cancer | 2020 |
| 32259783 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 30543347 | Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. | JAMA Oncol | 2019 |